NTRK1 and neoplasm: Exploration of molecular mechanisms of resistance used preclinical patient-derived xenograph (PDX) models established from the pre-treatment tumour of a patient with a CTRC-NTRK1 gene fusion-positive PDAC who had an acquired resistance to larotrectinib.